Literature DB >> 7675551

Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis.

W E Regelmann1, C M Siefferman, J M Herron, G R Elliott, C C Clawson, B H Gray.   

Abstract

Patients with cystic fibrosis (CF) of the same age differ significantly in their degree of pulmonary disease. Based on preliminary observations, we postulated that the activity of myeloperoxidase would be significantly increased in patients with greater structural lung damage than in those with less lung damage. Acid extracts of weighed sputum samples were assayed for lactoferrin concentrations by ELISA. Activities of peroxidase, cathespsin G, and elastase (with and without proteinase 3) were determined by kinetic analysis using chromogenic substrates. The patients were divided into quartiles based on their Brasfield chest-radiograph score. Patients in the first quartile (least amount of structural lung abnormality) were compared to those in the fourth quartile. The concentration of lactoferrin, a specific (secondary) granule protein of neutrophils, did not differ between the two patient groups. However, the activities of the neutrophil primary granule proteins, peroxidase, elastase, and elastase plus proteinase 3, were significantly elevated in the group with the most structural lung abnormality. Sputum albumin concentration was used to estimate leakages of plasma proteins into the airways. Peroxidase activity, but not the activity of cathepsin G, of elastase, or of elastase plus proteinase 3, correlated significantly with albumin/g sputum in both quartile groups. To confirm the association of sputum peroxidase activity with differences in lung structure and to test its correlation with lung function, spirometry was performed in a second group of patients during the week prior to the time of sputum sampling. In this second group, increased sputum peroxidase activity was associated with worse Brasfield scores and with decreased percent-predicted forced expiratory volume in 1 sec.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675551     DOI: 10.1002/ppul.1950190102

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  14 in total

1.  Immunological responses to respiratory syncytial virus infection in infancy.

Authors:  R L Smyth; J N Fletcher; H M Thomas; C A Hart
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  Inhibition of myeloperoxidase: evaluation of 2H-indazoles and 1H-indazolones.

Authors:  Aaron Roth; Sean Ott; Kelli M Farber; Teresa A Palazzo; Wayne E Conrad; Makhluf J Haddadin; Dean J Tantillo; Carroll E Cross; Jason P Eiserich; Mark J Kurth
Journal:  Bioorg Med Chem       Date:  2014-10-02       Impact factor: 3.641

Review 3.  The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

Authors:  M S Zach
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

4.  Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis.

Authors:  Ruchi Yadav; Dae-Goon Yoo; J Michelle Kahlenberg; S Louis Bridges; Oluwadamilola Oni; Hanwen Huang; Arlene Stecenko; Balázs Rada
Journal:  J Cyst Fibros       Date:  2019-01-10       Impact factor: 5.482

5.  Gene islands integrated into tRNA(Gly) genes confer genome diversity on a Pseudomonas aeruginosa clone.

Authors:  Karen D Larbig; Andreas Christmann; André Johann; Jens Klockgether; Thomas Hartsch; Rainer Merkl; Lutz Wiehlmann; Hans-Joachim Fritz; Burkhard Tümmler
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

6.  Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.

Authors:  Vihas T Vasu; Sharon J de Cruz; Jessica S Houghton; Keri A Hayakawa; Brian M Morrissey; Carroll E Cross; Jason P Eiserich
Journal:  Free Radic Res       Date:  2010-10-18

7.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

8.  Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation.

Authors:  Dae-goon Yoo; Matthew Winn; Lan Pang; Samuel M Moskowitz; Harry L Malech; Thomas L Leto; Balázs Rada
Journal:  J Immunol       Date:  2014-04-16       Impact factor: 5.422

Review 9.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 10.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.